Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics

Scientific advice — is drug repurposing missing a trick?

(2017) Pan Pantziarka   Nature Reviews Clinical Oncology

Cancer Drugs: An International Comparison of Postlicensing Price Inflation

(2017) Philip Savage et al.   Journal of Oncology Practice

In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of FGFR3 and a candidate anticancer drug for bladder carcinoma

(2016) Kunbin Ke et al.   Chemical Biology & Drug Design

Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma

(2016) K. Satoh et al.   CLINICAL CANCER RESEARCH

Busting the billion-dollar myth: how to slash the cost of drug development

(2016) Amy Maxmen   NATURE

In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma

(2016) Ziyan Y. Pessetto et al.   Oncotarget

Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data

(2016) Oktay Yildirim et al.   Frontiers in Pharmacology

Health Plan Utilization and Costs of Specialty Drugs Within 4 Chronic Conditions

(2016) Patrick P. Gleason et al.   JOURNAL OF MANAGED CARE PHARMACY

Computational and Practical Aspects of Drug Repositioning

(2015) Tudor I. Oprea et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

A survey of current trends in computational drug repositioning

(2015) Jiao Li et al.   BRIEFINGS IN BIOINFORMATICS

Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma

(2015) XI-NAN SHI et al.   Molecular Medicine Reports

Drug repurposing in oncology—patient and health systems opportunities

(2015) Francesco Bertolini et al.   Nature Reviews Clinical Oncology

In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug

(2015) Xi-Nan Shi et al.   PLoS One

Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents

(2014) Tahir Chohan et al.   CURRENT MEDICINAL CHEMISTRY

In silico identification of potential targets and drugs for non-small cell lung cancer

(2014) Chien-Hung Huang et al.   IET Systems Biology

Drug Repurposing Identifies a Synergistic Combination Therapy with Imatinib Mesylate for Gastrointestinal Stromal Tumor

(2014) Z. Y. Pessetto et al.   MOLECULAR CANCER THERAPEUTICS

CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence

(2014) Fumiya Hongo et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Identification of repurposed small molecule drugs for chordoma therapy

(2013) Menghang Xia et al.   CANCER BIOLOGY & THERAPY

Using computational strategies to predict potential drugs for nasopharyngeal carcinoma

(2013) Ming-Ying Lan et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Trifluoperazine, an Antipsychotic Agent, Inhibits Cancer Stem Cell Growth and Overcomes Drug Resistance of Lung Cancer

(2012) Chi-Tai Yeh et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Applications of Connectivity Map in drug discovery and development

(2012) Xiaoyan A. Qu et al.   DRUG DISCOVERY TODAY

Diagnosing the decline in pharmaceutical R&D efficiency

(2012) Jack W. Scannell et al.   NATURE REVIEWS DRUG DISCOVERY

An Integrated Bioinformatics Approach Identifies Elevated Cyclin E2 Expression and E2F Activity as Distinct Features of Tamoxifen Resistant Breast Tumors

(2011) Lei Huang et al.   PLoS One

Gene Expression-Based Chemical Genomics Identifies Potential Therapeutic Drugs in Hepatocellular Carcinoma

(2011) Ming-Huang Chen et al.   PLoS One

From NPC Therapeutic Target Identification to Potential Treatment Strategy

(2010) M.-Y. Lan et al.   MOLECULAR CANCER THERAPEUTICS

Lessons from 60 years of pharmaceutical innovation

(2009) Bernard Munos   NATURE REVIEWS DRUG DISCOVERY